ADVERSE REACTIONS
Central Nervous System
The most common manifestations encountered with phenytoin therapy are referable to this system and are usually dose-related. These include nystagmus, ataxia, slurred speech, decreased coordination, and mental confusion. Dizziness, insomnia, transient nervousness, motor twitchings, and headaches have also been observed. There have also been rare reports of phenytoin-induced dyskinesias, including chorea, dystonia, tremor, and asterixis, similar to those induced by phenothiazine and other neuroleptic drugs.
A predominantly sensory peripheral polyneuropathy has been observed in patients receiving long-term phenytoin therapy.
Gastrointestinal System
Nausea, vomiting, constipation, toxic hepatitis, and liver damage.
Integumentary System
Dermatological manifestations sometimes accompanied by fever have included scarlatiniform or morbilliform rashes. A morbilliform rash (measles-like) is the most common; other types of dermatitis are seen more rarely. Other more serious forms which may be fatal have included bullous, exfoliative or purpuric dermatitis, lupus erythematosus, Stevens-Johnson syndrome, and toxic epidermal necrolysis (see PRECAUTIONS section).
Hemopoietic System
Hemopoietic complications, some fatal, have occasionally been reported in association with administration of phenytoin. These have included thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression. While macrocytosis and megaloblastic anemia have occurred, these conditions usually respond to folic acid therapy. Lymphadenopathy including benign lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkin's disease have been reported (see WARNINGS section).
Connective Tissue System
Coarsening of the facial features, enlargement of the lips, gingival hyperplasia, hypertrichosis, and Peyronie's disease.
Immunologic
Hypersensitivity syndrome (which may include, but is not limited to, symptoms such as arthralgias, eosinophilia, fever, liver dysfunction, lymphadenopathy, or rash), systemic lupus erythematosus, periarteritis nodosa and immunoglobulin abnormalities.
|
REPORTS OF SUSPECTED DILANTIN SIDE EFFECTS / ADVERSE REACTIONS
Below is a sample of reports where side effects / adverse reactions may be related to Dilantin. The information is not vetted and should not be considered as verified clinical evidence.
Possible Dilantin side effects / adverse reactions in 52 year old female
Reported by a consumer/non-health professional from United States on 2011-10-03
Patient: 52 year old female weighing 44.5 kg (97.8 pounds)
Reactions: Product Substitution Issue, Urine Arsenic Increased, Sensory Loss, Toxicity TO Various Agents, Dysgeusia, Burning Sensation, Rash Erythematous, Poisoning, Blood Arsenic Increased
Adverse event resulted in: life threatening event, hospitalization
Suspect drug(s):
Dilantin
Possible Dilantin side effects / adverse reactions in 52 year old female
Reported by a consumer/non-health professional from United States on 2011-10-03
Patient: 52 year old female weighing 44.5 kg (97.8 pounds)
Reactions: Burning Sensation, Dysgeusia, Metal Poisoning, Rash Erythematous, Anticonvulsant Drug Level Increased, Sensory Disturbance, Toxicity TO Various Agents
Adverse event resulted in: life threatening event, hospitalization
Suspect drug(s):
Dilantin
Possible Dilantin side effects / adverse reactions in 52 year old female
Reported by a individual with unspecified qualification from United States on 2011-10-05
Patient: 52 year old female weighing 78.0 kg (171.6 pounds)
Reactions: Osteoporosis, Anticonvulsant Drug Level Decreased, Osteopenia, Tremor, Coordination Abnormal, Bone Density Decreased, Blood Creatinine Increased, Arthritis, Blood Glucose Increased
Suspect drug(s):
Topamax
Dosage: 1600 mg (400 mg,4 in 1 d)
Indication: Convulsion
Metformin HCL
Dosage: (500 mg)
Indication: Diabetes Mellitus
Dilantin
Dosage: (400 mg) ; (300 mg)
Indication: Convulsion
Other drugs received by patient: Synthroid
|
